TEVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Teva Pharmaceutical Industries Ltd (TEVA) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive catalysts such as FDA approvals and strong analyst support, the technical indicators and financial performance suggest a cautious approach. The stock's pre-market price movement is modest, and there is no strong trading signal from Intellectia Proprietary Trading Signals. Additionally, insider selling and a significant drop in net income and EPS in the latest quarter raise concerns. A hold action is recommended until clearer signs of sustained growth and stability emerge.
The MACD histogram is negative (-0.225) and contracting, indicating a weak bearish trend. RSI at 40.579 is neutral, showing no clear momentum. Moving averages are converging, suggesting indecision in the market. Key support is at 33.327, and resistance is at 34.992, with the current price near support levels.
FDA acceptance of the New Drug Application for TEV-749, a long-acting antipsychotic injectable for schizophrenia.
Analysts have consistently raised price targets, with Goldman Sachs and others highlighting strong execution and an improved business profile.
Revenue growth of 11.40% YoY in Q4 2025.
Insiders are selling shares, with a 102.27% increase in selling activity last month.
Net income and EPS dropped significantly in Q4 2025, down -321.20% and -315.79% YoY, respectively.
Technical indicators show no strong bullish signals, and the stock's short-term trend suggests a potential decline.
In Q4 2025, revenue increased by 11.40% YoY to $4.71 billion, and gross margin improved to 55.95%, up 8.20% YoY. However, net income dropped to $480 million (-321.20% YoY), and EPS fell to 0.41 (-315.79% YoY), indicating profitability challenges.
Analysts are bullish on TEVA, with multiple firms raising price targets recently. Goldman Sachs raised its target to $45, citing a fundamentally improved business profile and double-digit EPS growth potential. Other firms like Barclays, Scotiabank, and Jefferies also raised targets, reflecting confidence in the company's execution and pipeline.
